Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

134 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients.
Thomas D, McDonald VM, Stevens S, Harvey ES, Baraket M, Bardin P, Bowden JJ, Bowler S, Chien J, Chung LP, Gillman A, Hew M, Hodge S, James A, Jenkins C, Katelaris CH, Katsoulotos GP, Langton D, Lee J, Marks G, Peters M, Radhakrishna N, Reynolds PN, Rimmer J, Sivakumaran P, Upham JW, Wark P, Yang IA, Gibson PG. Thomas D, et al. Among authors: bowler s. Allergy. 2024 Feb;79(2):384-392. doi: 10.1111/all.15867. Epub 2023 Aug 25. Allergy. 2024. PMID: 37632144
Comorbidities Modify the Phenotype but Not the Treatment Effectiveness to Mepolizumab in Severe Eosinophilic Asthma.
Kritikos V, Harvey ES, Stevens S, Katelaris CH, Langton D, Rimmer J, Farah CS, Gillman A, Hew M, Radhakrishna N, Thomas D, Gibson PG; Australian Mepolizumab Registry Investigators. Kritikos V, et al. J Allergy Clin Immunol Pract. 2023 Mar;11(3):885-895.e13. doi: 10.1016/j.jaip.2022.12.004. Epub 2022 Dec 23. J Allergy Clin Immunol Pract. 2023. PMID: 36572182
Plasma Galectin-9 relates to cognitive performance and inflammation among adolescents with vertically acquired HIV.
Moar P, Linn K, Premeaux TA, Bowler S, Sardarni UK, Gopalan BP, Shwe EE, San T, Han H, Clements D, Hlaing CS, Kyu EH, Thair C, Mar YY, Nway N, Mannarino J, Bolzenius J, Mar S, Aye AMM, Tandon R, Paul R, Ndhlovu LC. Moar P, et al. Among authors: bowler s. AIDS. 2024 Apr 12. doi: 10.1097/QAD.0000000000003907. Online ahead of print. AIDS. 2024. PMID: 38608008
Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial.
Bennett C, Woo W, Bloch M, Cheung K, Griffin P, Mohan R, Deshmukh S, Arya M, Cumming O, Neville AM, McCallum Pardey TG, Plested JS, Cloney-Clark S, Zhu M, Kalkeri R, Patel N, Marcheschi A, Swan J, Smith G, Cho I, Glenn GM, Walker R, Mallory RM; Novavax 2019nCoV-311 Study Group. Bennett C, et al. Lancet Infect Dis. 2024 Mar 6:S1473-3099(24)00077-X. doi: 10.1016/S1473-3099(24)00077-X. Online ahead of print. Lancet Infect Dis. 2024. PMID: 38460525
134 results